OmegAD (Omega-3 and Alzheimer's Disease)
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00211159
- Lead Sponsor
- Karolinska University Hospital
- Brief Summary
Memory loss and difficulties with thinking associated with Alzheimer's disease (AD) may be due to a deficiency in the brain of a fatty acid named DHA. The aim of this trial is to see if dietary supplementation with a preparation, rich in DHA, will halt cognitive impairment in AD patients
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 204
Alzheimer's disease with MMSE 15-30, living in own homes, treated with stable dose of acetylcholine esterase inhibitor for >3 months and remaining on that treatment for the study period
Already treated with omega-3 fatty acids, NSAIDs, warfarin, being an alcohol abuser, suffering from serious concomitant disease or not having a caregiver
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Cognition measured according to ADAS-cog, MMSE scales
- Secondary Outcome Measures
Name Time Method Safety, tolerability, blood pressure Dose-response studies in relation to APOE4 status, to body weight and to gender 2007-2018 Analysis of changes of plasma and cerebrospinal fluid concentrations of omega-3 fatty acids in relation to APOE4 status, body weight and gender, as well as to changes in ADAS-cog and MMSE as measures of cognition.
Gene expression 2007-2018 mRNA expression and DNA methylation changes in blood leukocytes in relation to changes of plasma and cerebrospinal concentrations of omega-3 fatty acids
Trial Locations
- Locations (1)
Karolinska University Hospital Huddinge
🇸🇪Stockholm, Sweden